- Home
- TWO vs ATRC Comparison
TWO vs ATRC Comparison
Compare TWO & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- ATRC
- Stock Information
- Founded
- TWO 2009
- ATRC 2000
- Country
- TWO United States
- ATRC United States
- Employees
- TWO N/A
- ATRC N/A
- Industry
- TWO Real Estate Investment Trusts
- ATRC Medical/Dental Instruments
- Sector
- TWO Real Estate
- ATRC Health Care
- Exchange
- TWO Nasdaq
- ATRC Nasdaq
- Market Cap
- TWO N/A
- ATRC 1.5B
- IPO Year
- TWO 2009
- ATRC 2005
- Fundamental
- Price
- TWO $10.97
- ATRC $32.01
- Analyst Decision
- TWO Buy
- ATRC Strong Buy
- Analyst Count
- TWO 8
- ATRC 10
- Target Price
- TWO $13.53
- ATRC $48.50
- AVG Volume (30 Days)
- TWO 1.9M
- ATRC 556.9K
- Earning Date
- TWO 04-28-2025
- ATRC 04-29-2025
- Dividend Yield
- TWO 16.42%
- ATRC N/A
- EPS Growth
- TWO N/A
- ATRC N/A
- EPS
- TWO 2.37
- ATRC N/A
- Revenue
- TWO $622,055,000.00
- ATRC $465,307,000.00
- Revenue This Year
- TWO N/A
- ATRC $14.60
- Revenue Next Year
- TWO N/A
- ATRC $12.58
- P/E Ratio
- TWO $4.63
- ATRC N/A
- Revenue Growth
- TWO 144.06
- ATRC 16.55
- 52 Week Low
- TWO $10.16
- ATRC $18.94
- 52 Week High
- TWO $14.28
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- TWO 31.48
- ATRC 43.87
- Support Level
- TWO $10.77
- ATRC $29.48
- Resistance Level
- TWO $11.20
- ATRC $33.56
- Average True Range (ATR)
- TWO 0.58
- ATRC 2.13
- MACD
- TWO -0.13
- ATRC 0.14
- Stochastic Oscillator
- TWO 24.55
- ATRC 52.38
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.